Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Hematologic Oncology

Breast Cancer

Gastrointestinal Cancer

Hematologic Oncology

Gemtuzumab Ozogamicin Approved in Europe for CD33+ AML

The European Commission has approved the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg) for use in combination with daunorubicin and cytarabine for the treatment of patients aged 15 years and older with newly diagnosed, CD33-positive acute myeloid...
Read More >>

Hamlin Discusses Practice-Changing Data in Lymphoma

Following FDA Approvals, CML Pipeline Has Challenges

FDA Approval Sought for Gilteritinib in FLT3+ AML

FDA Halts Enrollment on Tazemetostat Trials

CAR T-Cell Therapy Starts to Enter MCL Space

View More Stories >>

View Conference Coverage

2018 AACR Annual Meeting

2018 European Lung Cancer Congress

2018 SGO Annual Meeting

2018 State of the Science Summit on Gastrointestinal Malignancies

2018 State of the Science Summit on Prostate Cancer

Dr. Usmani on Minimal Residual Disease in Multiple Myeloma

Dr. Bergsagel on Competing Philosophies of Treatment in Patients With Relapsed Myeloma

Dr. Htut on CAR T-Cell Therapy in Patients With Multiple Myeloma

CDK 4/6 Inhibitors in Mantle Cell Lymphoma

Dr. Nathwani on the Standard of Care in Patients With Newly Diagnosed Multiple Myeloma

Dr. Wolf on the Treatment of High-Risk Patients With Multiple Myeloma

Dr. Mesa Discusses the Management of Patients With MPNs

OncLive houses thousands of videos that provide updates and information.
See more Videos

Acute Lymphoblastic Leukemia: The Future of Treatment

Prevalence and Risk Factors for CMV Infection

$Role of CAR T-Cell Therapy in Relapsed/Refractory ALL$

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL

$Relapsed/Refractory ALL: Inotuzumab Ozogamicin$

$Relapsed/Refractory ALL: Evaluating Novel Agents$

$Approaching Treatment for Relapsed/Refractory ALL$

MRD-Positive ALL: Personal Approaches to Treatment

OncLive houses thousands of videos that provide updates and information.
See more Videos

Impact of Prognostic Factors on Clinical Decisions in CLL

Other Prognostic Factors in Chronic Lymphocytic Leukemia

TP53 and Deletion 17p as Prognostic Factors in CLL

Emerging Therapies for Follicular Lymphoma

FL: Updated Data for Immunomodulatory Approaches

Immunomodulatory Therapy for FL: The R-Squared Regimen

$Further Considerations for Relapsed/Refractory FL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

2015 ASH Annual Meeting Highlights

Gina Columbus highlights findings from the 2015 American Society of Hematology Annual Meeting and Exposition, including advances in multiple myeloma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.View Now

Multiple Myeloma: Emerging Concepts in Management

This Peer Exchange discussion, moderated by A. Keith Stuart, MB, ChB, highlights the most up-to-date information available on the emerging concepts in the management of multiple myeloma. View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

FDA Approvals in RCC and Chronic ITP, 2018 ELCC Highlights, and More